GlassScriptPhysician profile
Christopher Titsworth
NPI 1457047144
$8,898.84
in general payments reported to CMS, 2019-2025
32 companies · $2,329 in 2025
The $2,329 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,477 · 2024: $4,093 · 2025: $2,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,632 · Travel and Lodging: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,631.83 |
| Travel and Lodging | $1,267.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,703.01 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $849.58 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $829.95 | 2023-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $603.25 | 2023-2025 | |
| Ucb, INC. | $587.68 | 2023-2024 | Briviact, Rystiggo, Zilbrysq |
| Emd Serono, INC. | $584.89 | 2023-2024 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $537.26 | 2023-2025 | Xcopri |
| Pfizer INC. | $454.65 | 2023-2024 | |
| Eisai INC. | $363.76 | 2023-2025 | |
| Kyowa Kirin, INC. | $323.44 | 2023-2024 | Nourianz |
| Alexion Pharmaceuticals, INC. | $286.04 | 2023-2025 | Ultomiris, Soliris |
| Celgene Corporation | $218.42 | 2023-2024 | Zeposia |
| Lundbeck LLC | $180.46 | 2023-2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $151.29 | 2023-2024 | Austedo Xr, Ajovy |
| Genentech USA, INC. | $131.01 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $127.05 | 2023-2024 | Apokyn, Xadago, Myobloc |
| Ani Pharmaceuticals, INC. | $122.46 | 2023-2024 | Purified Cortrophin Gel |
| Catalyst Pharmaceuticals, INC. | $112.03 | 2023-2024 | Fycompa |
| Averitas Pharma INC. | $109.20 | 2023-2024 | Qutenza |
| Lilly USA, LLC | $105.53 | 2023-2025 | Zepbound, Emgality, Reyvow |
| Banner Life Sciences, LLC | $93.69 | 2023 | |
| Neurelis, INC. | $85.57 | 2024-2025 | Valtoco |
| Tanabe Pharma America, INC. | $67.54 | 2024 | |
| Amneal Pharmaceuticals LLC | $59.22 | 2023-2024 | Rytary |
| Otsuka America Pharmaceutical, INC. | $38.76 | 2024 | Nuedexta |
| Tg Therapeutics, INC. | $36.54 | 2025 | |
| Argenx US, INC. | $35.42 | 2023 | Vyvgart Hytrulo |
| Organogenesis INC. | $31.17 | 2025 | Puraply Wound Matrix |
| Impel Pharmaceuticals INC. | $23.78 | 2023 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $22.31 | 2023 | |
| Biogen, INC. | $15.34 | 2024 | Spinraza, Qalsody |
| Corium, LLC | $8.54 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Titsworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.